Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
It is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, which may lead to enhanced weight loss and metabolic effects compared to single or dual agonists
While most users join the regular program called, Noom Weight, Noom Med is ideal for : Individuals with a BMI of 30+ or 27+ with weight-related conditions who need medical support Those seeking a combination of behavioral change and medication for weight loss People without insurance or with limited coverage who can benefit from compounded medications Users committed to engaging with daily lessons and coaching for long-term success
Updated February 21, 2018
Hengruis oral GLP-1, HRS-7535, is expected to complete phase 2 trials shortly and its injectable candidate HRS-9531 is meanwhile fully engaged in phase 3 studies
US$ 22.69
US$ 20.19
US$ 28.31
US$ 29.76
